NZ333500A - Vaccines comprising HIV gp120 envelope polypeptides from vaccinees vaccinated with an earlier HIV gp120 vaccine and subsequently infected with HIV - Google Patents

Vaccines comprising HIV gp120 envelope polypeptides from vaccinees vaccinated with an earlier HIV gp120 vaccine and subsequently infected with HIV

Info

Publication number
NZ333500A
NZ333500A NZ333500A NZ33350097A NZ333500A NZ 333500 A NZ333500 A NZ 333500A NZ 333500 A NZ333500 A NZ 333500A NZ 33350097 A NZ33350097 A NZ 33350097A NZ 333500 A NZ333500 A NZ 333500A
Authority
NZ
New Zealand
Prior art keywords
hiv
vaccinated
vaccine
vaccinees
vaccines
Prior art date
Application number
NZ333500A
Other languages
English (en)
Inventor
Phillip W Berman
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of NZ333500A publication Critical patent/NZ333500A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NZ333500A 1996-07-08 1997-07-03 Vaccines comprising HIV gp120 envelope polypeptides from vaccinees vaccinated with an earlier HIV gp120 vaccine and subsequently infected with HIV NZ333500A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67673796A 1996-07-08 1996-07-08
PCT/US1997/009690 WO1998001564A1 (en) 1996-07-08 1997-07-03 Hiv envelope polypeptides and vaccine

Publications (1)

Publication Number Publication Date
NZ333500A true NZ333500A (en) 2000-09-29

Family

ID=24715764

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ333500A NZ333500A (en) 1996-07-08 1997-07-03 Vaccines comprising HIV gp120 envelope polypeptides from vaccinees vaccinated with an earlier HIV gp120 vaccine and subsequently infected with HIV

Country Status (13)

Country Link
US (1) US6090392A (OSRAM)
EP (1) EP0942988A1 (OSRAM)
JP (1) JP2000515368A (OSRAM)
AP (1) AP1282A (OSRAM)
AU (1) AU727107B2 (OSRAM)
CA (1) CA2259965A1 (OSRAM)
ID (1) ID17767A (OSRAM)
IL (2) IL127701A0 (OSRAM)
NZ (1) NZ333500A (OSRAM)
OA (1) OA10954A (OSRAM)
TW (1) TWI221846B (OSRAM)
WO (1) WO1998001564A1 (OSRAM)
ZA (1) ZA975889B (OSRAM)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6562347B1 (en) 1998-03-12 2003-05-13 The United States Of America As Represented By The Department Of Health And Human Services Chemokine-tumor antigen fusion proteins as cancer vaccines
AU785143B2 (en) 2000-02-04 2006-10-05 Beth Israel Deaconess Medical Center Human immunodeficiency virus vaccine
AU2001254567A1 (en) * 2000-05-02 2001-11-12 Simon Fraser University Polypeptides for use as a vaccine and/or treatment for hiv infection
AUPS065002A0 (en) 2002-02-20 2002-03-14 Immunaid Pty Ltd Strategy for retroviral immunotherapy
US20030228320A1 (en) * 2000-08-18 2003-12-11 Ashdown Martin Leonard Retroviral immunotherapy
AU2001291050A1 (en) 2000-09-15 2002-03-26 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Viral chemokine-tumur antigen fusion proteins
US7754676B2 (en) 2000-09-15 2010-07-13 The United States Of America As Represented By The Department Of Health And Human Services Defensin-antigen fusion proteins
CA2438515A1 (en) * 2001-02-15 2002-08-22 The Government Of The United States Of America Methods and compositions for inhibiting hiv-coreceptor interactions
AUPS054702A0 (en) * 2002-02-14 2002-03-07 Immunaid Pty Ltd Cancer therapy
EP1578766B1 (en) * 2002-12-03 2013-02-13 University of Massachusetts Polyvalent, primary hiv-1 glycoprotein dna vaccines and vaccination methods
CA2528005A1 (en) * 2003-06-12 2004-12-23 Vaxgen, Inc. Hiv-1 envelope glycoproteins having unusual disulfide structure
US8076060B2 (en) * 2003-08-04 2011-12-13 Emil William Chynn Vaccination and immunotherapy as new therapeutic modalities in the treatment of glaucoma
ATE490470T1 (de) * 2003-10-24 2010-12-15 Immunaid Pty Ltd Therapieverfahren
US20080248022A1 (en) * 2004-09-08 2008-10-09 Immunaid Pty Ltd Therapeutic Strategy for Treating Autoimmune and Degenerative Diseases
KR101450497B1 (ko) * 2004-09-14 2014-10-13 아고스 쎄라퓨틱스, 인코포레이티드 병원체의 균주 독립성 증폭 및 그에 대한 백신
JP2009509970A (ja) * 2005-09-22 2009-03-12 プロサイ インコーポレイテッド 酵母突然変異体において産生されるグリコシル化ポリペプチドおよびその使用方法
US8221981B2 (en) * 2007-07-30 2012-07-17 Argos Therapeutics, Inc. Primers and probes for the amplification and detection of HIV Gag, Rev and Nef polynucleotides
CA2735724C (en) 2008-06-19 2018-07-24 Variation Biotechnologies Inc. Compositions and methods for treating influenza
CA2763373C (en) 2009-05-27 2018-01-09 Immunaid Pty Ltd Methods and systems for determining preferred times for administering therapy to treat diseases
CA2803282C (en) 2009-07-06 2018-05-01 David E. Anderson Methods for preparing vesicles and formulations produced therefrom
WO2011005769A1 (en) 2009-07-06 2011-01-13 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
EP2550362B1 (en) 2010-03-25 2017-01-04 Oregon Health&Science University Cmv glycoproteins and recombinant vectors
CA2840079C (en) 2010-07-06 2018-07-03 Variation Biotechnologies Inc. Compositions and methods for treating influenza
MX359103B (es) 2011-01-13 2018-09-14 Variation Biotechnologies Inc Composiciones y sus usos en el tratamiento de infecciones virales.
RS57397B8 (sr) 2011-06-10 2020-01-31 Univ Oregon Health & Science Cmv glikoproteini i rekombinantni vektori
AU2012216792A1 (en) 2011-09-12 2013-03-28 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies
EP2586461A1 (en) 2011-10-27 2013-05-01 Christopher L. Parks Viral particles derived from an enveloped virus
US20140356399A1 (en) 2012-01-12 2014-12-04 Variation Biotechnologies, Inc. Compositions and methods for treating viral infections
WO2013111012A2 (en) 2012-01-27 2013-08-01 Variation Biotechnologies, Inc. Methods and compositions for therapeutic agents
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
CN104955847A (zh) 2012-12-04 2015-09-30 马里兰州大学(巴尔的摩) HIV-1 Env结合抗体、融合蛋白及其使用方法
EP2848937A1 (en) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Methods of identifying novel HIV-1 immunogens
EP2873423B1 (en) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3072901A1 (en) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3588134T2 (de) * 1984-12-24 1997-03-20 Genentech Inc Fusionen von AIDS-verwandten Polypeptiden
EP0279688B1 (en) * 1987-02-20 1997-04-16 Genentech, Inc. Methods and compositions for the use of HIV env polypeptides and antibodies thereto
IL89118A0 (en) * 1988-02-03 1989-08-15 Microgenesys Inc Vaccine containing polypeptides derived from the envelope gene of human immunodeficiency virus type 1
EP0339504A3 (en) * 1988-04-26 1990-09-12 The Du Pont Merck Pharmaceutical Company Human immunodeficiency virus (hiv) env-coded peptide capable of eliciting hiv-inhibiting antibodies in mammals
US5116740A (en) * 1988-08-16 1992-05-26 Akzo N.V. Method for producing native hiv gp160
CA2066607A1 (en) * 1989-09-22 1991-03-23 Thomas Kieber-Emmons Peptides associated with the cd4 binding region of gp120 and their methods of use
AU647108B2 (en) * 1990-04-03 1994-03-17 Genentech Inc. Methods and compositions for vaccination against HIV
AU7676891A (en) * 1990-04-03 1991-10-30 Genentech Inc. Hiv envelope polypeptides
EP0708659A4 (en) * 1993-06-07 2000-08-23 Genentech Inc HIV ENVELOPE POLYPEPTIDE

Also Published As

Publication number Publication date
EP0942988A1 (en) 1999-09-22
IL127701A (en) 2006-08-01
US6090392A (en) 2000-07-18
WO1998001564A1 (en) 1998-01-15
AP1282A (en) 2004-06-09
AP9901432A0 (en) 1999-03-31
ZA975889B (en) 1998-02-23
TWI221846B (en) 2004-10-11
AU3567797A (en) 1998-02-02
JP2000515368A (ja) 2000-11-21
IL127701A0 (en) 1999-10-28
OA10954A (en) 2001-10-25
AU727107B2 (en) 2000-11-30
ID17767A (id) 1998-01-22
CA2259965A1 (en) 1998-01-15

Similar Documents

Publication Publication Date Title
NZ333500A (en) Vaccines comprising HIV gp120 envelope polypeptides from vaccinees vaccinated with an earlier HIV gp120 vaccine and subsequently infected with HIV
AU2774389A (en) Recombinant vaccinia virus mva
IL140217A0 (en) Particles of hcv envelope proteins: use for vaccination
WO1998037095A3 (en) Recombinant pox virus for immunization against muc1 tumor-associated antigen
MY136081A (en) Modified hiv - 1gag p17 peptide and immunogenic composition
WO1993000365A3 (en) Hepatitis c virus (hcv) polypeptides
EP0752887A4 (en) RECOMBINANT IMMUNE WEAKNESS POX VIRUS
CA2660355A1 (en) Polynucleotide vaccine formulation against pathologies of the horse
CY2051B1 (en) Hiv-3 retrovirus and its use
HUP9900389A3 (en) Mixture of recombinant viruses as polyenv vaccines for hiv, preparation and use thereof
CA2082948A1 (en) Immunogenic peptides, antibodies and uses thereof relating to cd4 receptor binding
AU1353295A (en) Peptides derived from a retrovirus of the HIV group, and their use
NO912825D0 (no) Fremgangsmaate for fremstilling av cokonjugate vaksiner omfattende immunogenisk protein, hiv-beslektede peptider og anioniske grupper.
AU4826493A (en) Anti-feline immunodeficiency virus (fiv) vaccines
AU630861B2 (en) Recombinant hiv-2 polypeptides
AU4149699A (en) Use of inactivated immunosuppressive and/or angiogenic immunogenic proteins, preparation method and pharmaceutical or vaccine uses
NZ221227A (en) Hiv envelope proteins, antigenic fragments vaccines; and diagnostic methods
IE870507L (en) Bovine virus diarrhea and hog cholera vaccines
EP0762895A4 (en) SYNTHESIS VACCINE PROTECTING AGAINST HIV INFECTION
HK126095A (en) Hepatitis a virus vaccines
GB9818133D0 (en) Vaccine
WO1993014206A3 (en) Synthetic peptides for a rubella vaccine
AP1561A (en) Use of non-cytolytic retrovirus as vaccines for the treatment of HIV infection.
CA2370278A1 (en) Chimeric lyssavirus nucleic acids and polypeptides
ES2012815A6 (es) Un metodo para producir peptidos antigenicos relacionados con el antigeno p97 asociado a melanoma, y para preparar vacunas que los contienen.

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
EXPY Patent expired